SNNA Sienna Biopharmaceuticals Inc.

3.48
-0.63  -15%
Previous Close 4.11
Open 4.08
Price To Book 1.63
Market Cap 73567551
Shares 21,140,101
Volume 207,572
Short Ratio
Av. Daily Volume 89,895

SEC filingsSee all SEC filings

  1. 8-K - Current report 181230112
  2. 8-K - Current report 181212773
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168426
  4. 8-K - Current report 181168418
  5. 8-K - Current report 181105081

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due late January/early February 2019.
SNA-001
Reduction of light-pigmented hair
Phase 3 data released July 30, 2018 did not meet primary endpoint. Data from separate trial due late January/early February 2019.
SNA-001
Acne
Phase 2b trial did not meet primary endpoint. Phase 3 trial to be initiated 2H 2019.
SNA-120
Pruritus associated with psoriasis
Phase 1/2 data released August 27, 2018.
SNA-125
Psoriasis
Phase 1/2 commencement of dosing announced March 12, 2018 with top-line data due 4Q 2018.
SNA-125
Atopic dermatitis

SEC Filings

  1. 8-K - Current report 181230112
  2. 8-K - Current report 181212773
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168426
  4. 8-K - Current report 181168418
  5. 8-K - Current report 181105081
  6. 8-K - Current report 181038212
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181034999
  8. EFFECT - Notice of Effectiveness 181019632
  9. CORRESP [Cover] - Correspondence
  10. UPLOAD [Cover] - SEC-generated letter